NOVEMBER - 202219strategise and take the right action to remedy the situation. Cimon Medical is developing new probes towards this type of clinical application. By aiding clinicians in monitoring blood flow during cardiac surgery, it can reduce or avert clinical endpoints leading to blood vessel blockages."Our goal through these applications of doppler ultrasound is to become a market leader in continuous blood flow monitoring. We aim to address diverse use cases, from a critical newborn in the NICU to cardiac surgery and intervention. We will soon add more applications to help clinicians make timely, cost-effective, and accurate clinical decisions for the better sake of the patient," states Marzinski.Rising Market Acceptance of the Novel TechnologyCimon Medical is already receiving effective traction from the Nordic region's top-notch research centres and universities for including NeoDoppler in their clinical settings. The company wants to leverage these early adopters to evangelise the healthcare market, while showcasing NeoDoppler's clinical evidence to identify hemodynamic instability.The company is also planning a multi-centre pivotal study to provide more compelling clinical evidence from a clinician's standpoint. The multi-centre study would aim to conduct comparative effectiveness research to promote its technology's advantage over a predicate being identified as a non-invasive method of measuring blood flow, near-infrared spectroscopy (NIRS). Since NIRS is a measurement of brain tissue oxygenation, it may not fully explain blood flow and hemodynamic instability like Cimon Medical's device. Even if it does, NIRS provides an indirect estimate of CBF and cannot detect real-time fluctuation in circulation, like NeoDoppler. That makes Cimon Medical's offering unique and breakthrough from a clinical endpoint perspective. A Technology Backed by Sound Clinical and Business ExpertsOne of the biggest hurdles to any medtech startup's journey today is bringing superior technology to the market with the lowest possible capital investment. Cimon Medical efficiently jumps the hurdle because its talented team has diverse clinical, technology, and business expertise. Marzinski, for instance, has been a C-level executive for many medtech and life sciences companies in the past, with market knowledge in ophthalmology, interventional neuroradiology, interventional cardiology, robotic surgery, molecular diagnostics. He is also a strategic advisor, providing management consulting services to medical device companies on how to successfully launch products or expand footprints. He is not on an uncharted road when it comes to building high-performing teams or strategies that deliver superior value. Strong, deeply knowledgeable leadership is a major differentiator for the company. Their vast practical experience results in more productive yields with less capital. The company is backed by strong investors with two lead investors: Proventure and Investinor from Norway. They trust in the company's competency when it comes to ground-breaking clinical applications. With their continued support, Cimon Medical intends to reach new levels of innovation in continuous blood flow monitoring for developing new standards of care. Our goal through these applications of doppler ultrasound is to become a market leader in continuous blood flow monitoring. We aim to address diverse use cases, from a critical newborn in the NICU to cardiac surgery and intervention
< Page 9 | Page 11 >